Sana Biotechnology SANA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -118.7%-19.5pp | -99.2%-27.2pp | -72%-28.1pp | -43.9%— | |
| Return on assets | -53.2%-3.2pp | -50%-9.2pp | -40.8%-13.2pp | -27.6%+10.7pp | |
| Return on invested capital | -130%-15.3pp | -114.8%-29.7pp | -85.1%-31.5pp | -53.6%— | |
| Liquidity | |||||
| Current ratio | 1.9×-1.7× | 3.5×+0.2× | 3.3×-0.7× | 4×-1.6× | |
| Quick ratio | 1.9×-1.7× | 3.5×+0.2× | 3.3×-0.7× | 4×-1.6× | |
| Cash ratio | 0.9×-1.9× | 2.8×+0.7× | 2.1×+0.5× | 1.6×-1.0× | |
| Leverage | |||||
| Debt-to-equity | 0.5×+0.1× | 0.4×0.0× | 0.4×+0.1× | 0.2×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | 0.1×0.0× | |
| Interest coverage | -65.1×-39.0× | -26×+3.5× | -29.5×+43.0× | -72.5×+456× | |
| Per Share | |||||
| Book value per share | $0.64-41.4% | $1.08-26.6% | $1.48-44.3% | $2.65-39.4% | |
| Valuation | |||||
| Market capitalization | $907.23M+54.1% | $363.93M-54.8% | $805.05M+7.0% | $752.16M-73.9% | |
| Enterprise value | $898.76M+53.9% | $330.56M-57.4% | $775.63M+13.5% | $683.65M-75.0% | |
| Price / book | 7.6×+4.8× | 1.5×-1.3× | 2.8×+1.3× | 1.5×-2.4× | |
| Free cash flow yield | -14.7%+23.3pp | -70.5%-36.5pp | -34%+7.4pp | -41.3%-31.6pp | |
| Earnings yield | -26.7%+8.8pp | -73.3%-38.1pp | -35.2%+0.6pp | -35.8%-23.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sana Biotechnology's ratios come from?
- Every ratio is computed from Sana Biotechnology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.